Mirna Therapeutics Inc. (NASDAQ:MIRN)’s share price dropped 8.7% on Thursday . The stock traded as low as $3.05 and last traded at $3.06, with a volume of 99,486 shares. The stock had previously closed at $3.35.

MIRN has been the topic of several recent research reports. Oppenheimer Holdings Inc. increased their price objective on shares of Mirna Therapeutics from $7.00 to $13.00 and gave the stock an “outperform” rating in a research note on Tuesday. Leerink Swann cut shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $10.00 to $4.00 in a research note on Monday. Citigroup Inc. cut shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $7.00 to $4.50 in a research note on Tuesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price objective on shares of Mirna Therapeutics in a research note on Friday, May 13th. Finally, Zacks Investment Research upgraded shares of Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Thursday, July 14th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $8.10.

The stock’s market capitalization is $62.92 million. The stock has a 50 day moving average of $4.26 and a 200-day moving average of $4.37.

Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.